Envestnet Asset Management Inc. Has $70.59 Million Stock Holdings in argenex SE $ARGX

Envestnet Asset Management Inc. lifted its holdings in shares of argenex SE (NASDAQ:ARGX) by 10.2% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 95,711 shares of the company’s stock after buying an additional 8,850 shares during the period. Envestnet Asset Management Inc. owned about 0.16% of argenex worth $70,593,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of ARGX. Mather Group LLC. bought a new stake in argenex during the 3rd quarter worth $50,000. TD Private Client Wealth LLC raised its holdings in argenex by 750.0% in the 3rd quarter. TD Private Client Wealth LLC now owns 85 shares of the company’s stock valued at $63,000 after buying an additional 75 shares during the last quarter. MAI Capital Management boosted its position in argenex by 866.7% during the 2nd quarter. MAI Capital Management now owns 87 shares of the company’s stock worth $48,000 after buying an additional 78 shares during the period. Financial Consulate Inc. bought a new stake in argenex during the 3rd quarter worth approximately $75,000. Finally, Global Retirement Partners LLC increased its position in argenex by 42.7% in the 3rd quarter. Global Retirement Partners LLC now owns 107 shares of the company’s stock valued at $79,000 after acquiring an additional 32 shares during the period. 60.32% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Wedbush reiterated an “outperform” rating and set a $1,000.00 price target on shares of argenex in a report on Wednesday, January 14th. Wolfe Research reaffirmed a “peer perform” rating on shares of argenex in a research report on Monday, November 24th. JPMorgan Chase & Co. upped their price target on argenex from $925.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Monday, December 8th. Wall Street Zen cut argenex from a “buy” rating to a “hold” rating in a research note on Sunday. Finally, Morgan Stanley lifted their price objective on argenex from $1,070.00 to $1,110.00 and gave the stock an “overweight” rating in a research note on Thursday, December 4th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $986.78.

argenex Price Performance

Shares of argenex stock opened at $811.45 on Monday. argenex SE has a one year low of $510.05 and a one year high of $934.62. The stock’s 50-day moving average is $844.08 and its 200 day moving average is $793.69. The firm has a market cap of $50.21 billion, a price-to-earnings ratio of 34.84, a PEG ratio of 0.70 and a beta of 0.37.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.